A study investigating the effect of curcumin on the absorption and elimination of IMU 838, a new compound that may potentially be used in the treatment of multiple sclerosis, and the effect of IMU 838 on the absorption and elimination of rosuvastatin.

开始日期2026-01-08

申办/合作机构

Immunic AG

CTIS2025-521754-41-00

/ Not yet recruiting临床1期

A Phase 1, Single-Center, Open-Label, Fixed-Sequence, 2-Part Study to Assess the Pharmacokinetics of IMU-838 Administered Alone and in Combination with Multiple Doses of Gemfibrozil as CYP2C8 Inhibitor, or Rifampicin as CYP2C8 Inducer, in Healthy Subjects

开始日期2025-08-15

申办/合作机构

Immunic AG

100 项与 Vidofludimus calcium 相关的临床结果

登录后查看更多信息

100 项与 Vidofludimus calcium 相关的转化医学

登录后查看更多信息

100 项与 Vidofludimus calcium 相关的专利（医药）

登录后查看更多信息

项与 Vidofludimus calcium 相关的文献（医药）

2025-10-01·Molecular Metabolism

Inhibition of pyrimidine de novo synthesis fosters Treg cells and reduces diabetes development in models of Type 1 Diabetes

Article

作者: Hintermann, Edith ; Dirschl, Sandra M ; Kohlhof, Hella ; Tondello, Camilla ; Johannsmann, Till M ; Gmehling, Hanna ; Serr, Isabelle ; Hipp, Hannah ; Stavridou, Antigoni ; Christen, Urs ; Bührer, Anne-Marie ; Daniel, Carolin ; Becker, Maike ; Scherm, Martin G ; Scholz, Lena K

OBJECTIVE:

In autoimmune Type 1 Diabetes (T1D), aberrant immune activation promotes regulatory T cell (Treg) impairments thereby boosting progression of islet autoimmunity. Consequently, there is a progressive destruction of the insulin-producing beta cells in the pancreas. Controlling overshooting immune activation represents a relevant approach to allow for efficient Treg-targeting by broadening the window of opportunity to induce Tregs.

METHODS:

We investigated the effect of restricting pyrimidine de novo synthesis during islet autoimmunity and T1D by Dihydroorotate dehydrogenase (DHODH) inhibition using the next-generation DHODH inhibitor Vidofludimus calcium. We assessed Treg-inducing features of DHODH inhibition in T cells from ongoing murine islet autoimmunity and human T1D in vitro. To dissect the functional relevance of these observations, we tested the impact of DHODH inhibition on interfering with autoimmune activation and disease progression in pre-clinical models of T1D in vivo.

RESULTS:

We show that DHODH inhibition results in enhanced Treg induction in vitro especially during increased immune activation and reduced T cell proliferation. In addition, Vidofludimus calcium reduced T1D incidence in two mouse models. On the cellular level, treated mice showed reduced T cell activation accompanied by increased Treg frequencies.

CONCLUSIONS:

We demonstrate that restricting pyrimidine de novo synthesis by next-generation DHODH inhibition is a strategy to interfere with autoimmune activation while fostering Tregs.

2024-10-01·ChemMedChem

Synthesis and Characterization of DHODH Inhibitors Based on the Vidofludimus Scaffold with Pronounced Anti‐SARS‐CoV‐2 Activity

Article

作者: Eberlein, Valentina ; Issmail, Leila ; Kohlhof, Hella ; Häge, Sigrun ; Hahn, Friedrich ; Wangen, Christina ; Herrmann, Alexandra ; Vitt, Daniel ; Marschall, Manfred ; Klopfleisch, Robert ; Uhlig, Nadja ; Gege, Christian ; Grunwald, Thomas

Abstract:

New strategies for the rapid development of broad‐spectrum antiviral therapies are urgently required for emerging and re‐emerging viruses like the severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2). Host‐directed antivirals that target universal cellular metabolic pathways necessary for viral replication present a promising approach with broad‐spectrum activity and low potential for development of viral resistance. Dihydroorotate dehydrogenase (DHODH) was identified as one of those universal host factors essential for the replication of many clinically relevant human pathogenic viruses. DHODH is the rate‐limiting enzyme catalyzing the fourth step in the de novo pyrimidine synthesis. Therefore, it is also developed as a therapeutic target for many diseases relying on cellular pyrimidine resources, such as cancer, autoimmune diseases and viral or bacterial infection. Thus, several DHODH inhibitors, including vidofludimus calcium (VidoCa, IMU‐838), are currently in development or have been investigated in clinical trials for the treatment of virus infections such as SARS‐CoV‐2‐mediated coronavirus disease 19 (COVID‐19). Here, we report the medicinal chemistry optimization of VidoCa that resulted in metabolically more stable derivatives with improved DHODH target inhibition in various mammalian species, which translated into improved efficacy against SARS‐CoV‐2.

2024-05-01·Neurology(R) neuroimmunology & neuroinflammation

Safety and Dose-Response of Vidofludimus Calcium in Relapsing Multiple Sclerosis

Article

作者: Sellner, Johann ; De Stefano, Nicola ; Wolf, Christian ; Kohlhof, Hella ; Bozhinov, Plamen S ; Gryb, Viktoriia ; Sciacca, Valentina ; Vitt, Daniel ; Wiendl, Heinz ; Rejdak, Konrad ; Ondrus, Matej ; Slizgi, Jason ; Muehler, Andreas R ; Fox, Robert J

BACKGROUND AND OBJECTIVES:

Vidofludimus calcium suppressed MRI disease activity compared with placebo in patients with relapsing-remitting multiple sclerosis (RRMS) in the first cohort of the phase 2 EMPhASIS study. Because 30 mg and 45 mg showed comparable activity on multiple end points, the study enrolled an additional low-dose cohort to further investigate a dose-response relationship.

METHODS:

In a randomized, placebo-controlled, phase 2 trial, patients with RRMS, aged 18-55 years, and with ≥2 relapses in the last 2 years or ≥1 relapse in the last year, and ≥1 gadolinium-enhancing brain lesion in the last 6 months. Patients were randomly assigned (1:1:1) vidofludimus calcium (30 or 45 mg) or placebo in cohort 1 and vidofludimus calcium (10 mg) or placebo (4:1) in cohort 2 for 24 weeks. The primary end point was the cumulative number of combined unique active (CUA) lesions at week 24. Secondary end points were clinical outcomes and safety.

RESULTS:

Across cohorts 1 and 2, 268 patients were randomized to placebo (n = 81), 10 mg (n = 47) vidofludimus calcium, 30 mg (n = 71) vidofludimus calcium, or 45 mg (n = 69) vidofludimus calcium. The mean cumulative CUA lesions over 24 weeks was 5.8 (95% CI 4.1-8.2) for placebo, 5.9 (95% CI 3.9-9.0) for 10 mg treatment group, 1.4 (95% CI 0.9-2.1) for 30 mg treatment group, and 1.7 (95% CI 1.1-2.5) for 45 mg treatment group. Serum neurofilament light chain decreased in a dose-dependent manner. The number of patients with confirmed disability worsening after 24 weeks was 3 (3.7%) patients receiving placebo and 3 (1.6%) patients receiving any dose of vidofludimus calcium. Treatment-emergent adverse events occurred in 35 (43%) placebo patients compared with 11 (23%) and 71 (37%) patients in the 10 mg or any dose of vidofludimus calcium groups, respectively. The incidence of liver enzyme elevations and infections were similar between placebo and any dose of vidofludimus calcium. No new safety signals were observed.

DISCUSSION:

Compared with placebo, vidofludimus calcium suppressed the development of new brain lesions with daily doses of 30 mg and 45 mg, but not 10 mg, establishing the lowest efficacious dose is 30 mg.

CLASSIFICATION OF EVIDENCE:

This study provides Class II evidence that among adults with active RRMS and ≥1 Gd+ brain lesion in the past 6 months, the cumulative number of active lesions decreased with vidofludimus calcium.

TRIAL REGISTRATION INFORMATION:

ClinicalTrials.gov (NCT03846219) and EudraCT (2018-001896-19).

129

项与 Vidofludimus calcium 相关的新闻（医药）

2026-05-01

·FierceBiotech

Chutes & Ladders—Astellas appoints new top strategist from Sanofi Japan

None\n Welcome to this week\'s Chutes & Ladders, our roundup of significant leadership hirings, firings and retirings across the industry. Please send the good word—or the bad—from your shop to Darren Incorvaia or Zoey Becker and it will be featured here at the end of each week.Astellas appoints new top strategist from Sanofi JapanAstellas Pharma After last month’s departure of longtime executive Adam Pearson, Astellas has picked out a new strategist to fill the open spot on its C-suite with Takahiko Iwaya, who takes over as chief strategy officer on July 1. Before embarking on a career within biopharma leadership, Iwaya joined what is now Japan’s Ministry of Health, Labour and Welfare in 1990, where he worked on healthcare systems and policies for 14 years. After that, the executive held various leadership positions at Johnson & Johnson Japan before joining Sanofi’s Japan unit in 2019. In June, the executive will step down from his current role as president and representative director at Sanofi Japan, as well as depart his role as chair of the European Federation of Pharmaceutical Industries and Associations, Japan. He takes over the strategy role at Astellas from Peter Sandor, M.D., who has been holding down the fort on an interim basis since Pearson’s resignation. ReleaseImmunic preps for approval push with pharma vetImmunicAs a critical phase 3 readout for its multiple sclerosis candidate rapidly approaches, Immunic is shoring up its leadership with Michael Panzara, M.D., as chief medical officer. Panzara previously oversaw the approvals of other MS medicines like Biogen’s Tysabri and Sanofi’s Lemtrada and Aubagio. Panzara takes over for the departing Andreas Muehler, M.D., who is also a co-founder of Immunic. Immunic’s vidofludimus calcium is currently being tested in a pair of phase 3 trials, though the candidate previously failed to hit the primary endpoint of a phase 2 study. ReleaseCardiologist turns new leaf at NuevocorNuevocorCardio-focused Nuevocor is making a hearty change to its C-suite, bringing in experienced cardiologist Monica Shah, M.D., as chief medical officer. Shah brings a wealth of cell and gene therapy experience, including stints leading the global AAV program at Rocket Pharmaceuticals and the cell and gene therapy division of IQVIA. She built her career with a nearly nine-year tenure at the National Institutes of Health, mostly as the deputy chief of heart failure and arrhythmias at the National Heart, Lung, and Blood Institute. Nuevocor is counting on Shah to guide first-in-human studies of NVC-001, the biotech’s lead gene therapy for cardiomyopathy. Release> AI-focused vaccine maker Evaxion is opting for a dual role for chief scientific officer Birgitte Rønø, who has now been promoted to chief operating officer as well. Release> Convergent Therapeutics is bringing in seasoned dealmaker Andrew Davis to serve as chief business and strategy officer. Release> Longtime CEO Eric Goupil is handing over the reins at global contract manufacturer Unither Pharmaceuticals, with Henrik Krüpper lined up to take his place on May 4. Release> Hot off a deal with Merck & Co., antibody outfit Infinimmune is upping its pipeline tactics with Anthony Slavin, Ph.D., as senior vice president of portfolio strategy. Release> British cell and gene CDMO eXmoor Pharma is welcoming former Catalent CEO George Fotiades as chair, while founder Angela Osborne steps back from the role. Release> Synthetic biology specialist Manus Bio has named Baljit Ghotra, Ph.D., as senior vice president of innovation and operations. Release

高管变更临床3期

2026-04-30

·PRNewswire

Immunic to Participate in Investor and Medical Conferences in May

NEW YORK, April 30, 2026 /PRNewswire/ -- Immunic , Inc. (Nasdaq: IMUX), a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic diseases, today announced participation in the following investor and medical conferences in May: May 4-6 and 12-13: 26th Bio€quity Europe. Daniel Vitt, Ph.D., Chief Executive Officer of Immunic, and Jessica Breu, Vice President Investor Relations and Communications at Immunic, will attend and host one-on-one investor meetings at this conference taking place in Prague, Czech Republic and virtually. To schedule a meeting, please use the Bio€quity Europe conference portal or contact Jessica Breu at: [email protected]. May 27-29: 2026 Consortium of Multiple Sclerosis Centers (CMSC) Annual Meeting. Members of Immunic's management, medical and preclinical teams will attend this meeting in Charlotte, NC. One late-breaking poster and two additional posters have been accepted for presentation and will be accessible on the "Events and Presentations" section of Immunic's website at: . Additionally, the team will be available throughout the event at booth #307. Late-Breaking Poster Presentation: Title: Novel Unified Statistical Analyses for Confirmed Disability Changes In Multiple Sclerosis for Capturing Possible Neuroprotective Effects Presenting Author: James Myles, Global Head of Biostatistics at Immunic Abstract ID: 11244 Poster Board Label: LBA14 Session Date: Thursday, May 28, 2026 Session Time: 5:00-7:00 pm ET Location: Exhibit Hall Poster Presentations: Title: Effect of Vidofludimus Calcium, a Direct Nurr1 Activator and Selective DHODH Inhibitor, on Patient-Reported Outcomes (PRO) in Progressive MS: Data from Phase 2 CALLIPER Trial Presenting Author: Julie Korich, Ph.D., Senior Medical Director, Medical Affairs at Immunic Abstract ID: 10843 Poster Board Label: DMT10 Session Date: Thursday, May 28, 2026 Session Time: 5:00-7:00 pm ET Location: Exhibit Hall B Title: Safety and Tolerability of Vidofludimus Calcium, a Direct Nurr1 Activator and Selective DHODH Inhibitor: Data from Phase 2 CALLIPER Trial Presenting Author: Alex Lublin, Ph.D., Senior Medical Director, Medical Affairs at Immunic Abstract ID: 10995 Poster Board Label: DMT11 Session Date: Thursday, May 28, 2026 Session Time: 5:00-7:00 pm ET Location: Exhibit Hall B About Immunic, Inc. Immunic, Inc. (Nasdaq: IMUX) is a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic diseases. The company's lead development program, vidofludimus calcium (IMU-838), is currently in phase 3 clinical trials for the treatment of relapsing multiple sclerosis, for which top-line data is expected to be available by the end of 2026. It has already shown therapeutic activity in phase 2 clinical trials in relapsing-remitting multiple sclerosis, progressive multiple sclerosis and other diseases. Vidofludimus calcium combines neuroprotective effects, through its mechanism as a first-in-class nuclear receptor-related 1 (Nurr1) activator, with additional anti-inflammatory and anti-viral effects, by selectively inhibiting the enzyme dihydroorotate dehydrogenase (DHODH). The company's development pipeline also includes earlier-stage programs, including IMU-856 and IMU-381, aimed at building a broader therapeutics platform addressing neurodegenerative, chronic inflammatory, and autoimmune-related diseases. For further information, please visit: . Cautionary Statement Regarding Forward-Looking Statements This press release contains "forward-looking statements" that involve substantial risks and uncertainties for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical facts, included in this press release regarding strategy, future operations, future financial position, future revenue, projected expenses, sufficiency of cash and cash runway, expected timing, development and results of clinical trials, prospects, plans and objectives of management are forward-looking statements. Examples of such statements include, but are not limited to, statements relating to management's and employee's participation in investor and medical conferences. Immunic may not actually achieve the plans, carry out the intentions or meet the expectations or projections disclosed in the forward-looking statements and you should not place undue reliance on these forward-looking statements. Such statements are based on management's current expectations and involve substantial risks and uncertainties. Actual results and performance could differ materially from those projected in the forward-looking statements as a result of many factors, including, without limitation, increasing inflation, tariffs and macroeconomics trends, impacts of the Ukraine – Russia conflict and the conflict in the Middle East on planned and ongoing clinical trials, risks and uncertainties associated with the ability to project future cash utilization and reserves needed for contingent future liabilities and business operations, the availability of sufficient financial and other resources to meet business objectives and operational requirements, the fact that the results of earlier preclinical studies and clinical trials may not be predictive of future clinical trial results, any changes to the size of the target markets for the company's products or product candidates, the protection and market exclusivity provided by Immunic's intellectual property, risks related to the drug development and the regulatory approval process and the impact of competitive products and technological changes. A further list and descriptions of these risks, uncertainties and other factors can be found in the section captioned "Risk Factors," in the company's Annual Report on Form 10-K for the fiscal year ended December 31, 2025, filed with the SEC on February 26, 2026, and in the company's subsequent filings with the SEC. Copies of these filings are available online at or ir.imux.com/sec-filings. Any forward-looking statement made in this release speaks only as of the date of this release. Immunic disclaims any intent or obligation to update these forward-looking statements to reflect events or circumstances that exist after the date on which they were made. Immunic expressly disclaims all liability in respect to actions taken or not taken based on any or all of the contents of this press release. Contact Information Immunic, Inc. Jessica Breu Vice President Investor Relations and Communications +49 89 2080 477 09 [email protected] US IR Contact Rx Communications Group Paula Schwartz +1 917 633 7790 [email protected] US Media Contact KCSA Strategic Communications Caitlin Kasunich +1 212 896 1241 [email protected] SOURCE Immunic, Inc. 21% more press release views with Request a Demo

临床2期临床3期临床结果

2026-04-30

·BioSpace

Immunic to Participate in Investor and Medical Conferences in May 2026

NEW YORK , April 30, 2026 /PRNewswire/ -- Immunic , Inc. (Nasdaq: IMUX), a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic diseases, today announced participation in the following investor and medical conferences in May: May 4-6 and 12-13: 26th Bio€quity Europe. Daniel Vitt, Ph.D., Chief Executive Officer of Immunic, and Jessica Breu, Vice President Investor Relations and Communications at Immunic, will attend and host one-on-one investor meetings at this conference taking place in Prague, Czech Republic and virtually. To schedule a meeting, please use the Bio€quity Europe conference portal or contact Jessica Breu at: jessica.breu@imux.com . May 27-29: 2026 Consortium of Multiple Sclerosis Centers (CMSC) Annual Meeting. Members of Immunic's management, medical and preclinical teams will attend this meeting in Charlotte, NC. One late-breaking poster and two additional posters have been accepted for presentation and will be accessible on the "Events and Presentations" section of Immunic's website at: . Additionally, the team will be available throughout the event at booth #307. Late-Breaking Poster Presentation: Title: Novel Unified Statistical Analyses for Confirmed Disability Changes In Multiple Sclerosis for Capturing Possible Neuroprotective Effects Presenting Author: James Myles, Global Head of Biostatistics at Immunic Abstract ID: 11244 Poster Board Label: LBA14 Session Date: Thursday, May 28, 2026 Session Time: 5:00-7:00 pm ET Location: Exhibit Hall Poster Presentations: Title: Effect of Vidofludimus Calcium, a Direct Nurr1 Activator and Selective DHODH Inhibitor, on Patient-Reported Outcomes (PRO) in Progressive MS: Data from Phase 2 CALLIPER Trial Presenting Author: Julie Korich, Ph.D., Senior Medical Director, Medical Affairs at Immunic Abstract ID: 10843 Poster Board Label: DMT10 Session Date: Thursday, May 28, 2026 Session Time: 5:00-7:00 pm ET Location: Exhibit Hall B Title: Safety and Tolerability of Vidofludimus Calcium, a Direct Nurr1 Activator and Selective DHODH Inhibitor: Data from Phase 2 CALLIPER Trial Presenting Author: Alex Lublin, Ph.D., Senior Medical Director, Medical Affairs at Immunic Abstract ID: 10995 Poster Board Label: DMT11 Session Date: Thursday, May 28, 2026 Session Time: 5:00-7:00 pm ET Location: Exhibit Hall B About Immunic, Inc. Immunic, Inc. (Nasdaq: IMUX) is a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic diseases. The company's lead development program, vidofludimus calcium (IMU-838), is currently in phase 3 clinical trials for the treatment of relapsing multiple sclerosis, for which top-line data is expected to be available by the end of 2026. It has already shown therapeutic activity in phase 2 clinical trials in relapsing-remitting multiple sclerosis, progressive multiple sclerosis and other diseases. Vidofludimus calcium combines neuroprotective effects, through its mechanism as a first-in-class nuclear receptor-related 1 (Nurr1) activator, with additional anti-inflammatory and anti-viral effects, by selectively inhibiting the enzyme dihydroorotate dehydrogenase (DHODH). The company's development pipeline also includes earlier-stage programs, including IMU-856 and IMU-381, aimed at building a broader therapeutics platform addressing neurodegenerative, chronic inflammatory, and autoimmune-related diseases. For further information, please visit: . Cautionary Statement Regarding Forward-Looking Statements This press release contains "forward-looking statements" that involve substantial risks and uncertainties for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical facts, included in this press release regarding strategy, future operations, future financial position, future revenue, projected expenses, sufficiency of cash and cash runway, expected timing, development and results of clinical trials, prospects, plans and objectives of management are forward-looking statements. Examples of such statements include, but are not limited to, statements relating to management's and employee's participation in investor and medical conferences. Immunic may not actually achieve the plans, carry out the intentions or meet the expectations or projections disclosed in the forward-looking statements and you should not place undue reliance on these forward-looking statements. Such statements are based on management's current expectations and involve substantial risks and uncertainties. Actual results and performance could differ materially from those projected in the forward-looking statements as a result of many factors, including, without limitation, increasing inflation, tariffs and macroeconomics trends, impacts of the Ukraine – Russia conflict and the conflict in the Middle East on planned and ongoing clinical trials, risks and uncertainties associated with the ability to project future cash utilization and reserves needed for contingent future liabilities and business operations, the availability of sufficient financial and other resources to meet business objectives and operational requirements, the fact that the results of earlier preclinical studies and clinical trials may not be predictive of future clinical trial results, any changes to the size of the target markets for the company's products or product candidates, the protection and market exclusivity provided by Immunic's intellectual property, risks related to the drug development and the regulatory approval process and the impact of competitive products and technological changes. A further list and descriptions of these risks, uncertainties and other factors can be found in the section captioned "Risk Factors," in the company's Annual Report on Form 10-K for the fiscal year ended December 31, 2025, filed with the SEC on February 26, 2026, and in the company's subsequent filings with the SEC. Copies of these filings are available online at or ir.imux.com/sec-filings. Any forward-looking statement made in this release speaks only as of the date of this release. Immunic disclaims any intent or obligation to update these forward-looking statements to reflect events or circumstances that exist after the date on which they were made. Immunic expressly disclaims all liability in respect to actions taken or not taken based on any or all of the contents of this press release. Contact Information Immunic, Inc. Jessica Breu Vice President Investor Relations and Communications +49 89 2080 477 09 jessica.breu@imux.com US IR Contact Rx Communications Group Paula Schwartz +1 917 633 7790 immunic@rxir.com US Media Contact KCSA Strategic Communications Caitlin Kasunich +1 212 896 1241 ckasunich@kcsa.com View original content to download multimedia: SOURCE Immunic, Inc.

临床2期临床3期

100 项与 Vidofludimus calcium 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
复发-缓解型多发性硬化	临床3期	美国	Immunic AG	2022-01-12
复发-缓解型多发性硬化	临床3期	亚美尼亚	Immunic AG	2022-01-12
复发-缓解型多发性硬化	临床3期	波斯尼亚和黑塞哥维那	Immunic AG	2022-01-12
复发-缓解型多发性硬化	临床3期	爱沙尼亚	Immunic AG	2022-01-12
复发-缓解型多发性硬化	临床3期	德国	Immunic AG	2022-01-12
复发-缓解型多发性硬化	临床3期	印度	Immunic AG	2022-01-12
复发-缓解型多发性硬化	临床3期	秘鲁	Immunic AG	2022-01-12
复发-缓解型多发性硬化	临床3期	波兰	Immunic AG	2022-01-12
复发-缓解型多发性硬化	临床3期	罗马尼亚	Immunic AG	2022-01-12
复发-缓解型多发性硬化	临床3期	塞尔维亚	Immunic AG	2022-01-12

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT05054140 (CALLIPER, NEWS) 人工标引	临床2期	多发性硬化症	467	Vidofludimus Calcium	蓋餘夢齋積積窪鹽築膚(製廠壓網鬱蓋觸蓋獵鬱) = 製淵構積蓋築獵積顧襯憲壓淵糧艱窪憲願膚膚 (顧鑰蓋衊鹹窪選膚襯鬱 )	积极	2025-09-25
				Placebo	繭築構蓋選糧顧鏇鑰夢(鏇醖壓餘鬱鏇選製窪顧) = 蓋簾鹹醖積鹽襯積夢網鑰廠衊鑰簾艱鏇觸衊糧 (醖廠醖網選齋範蓋顧範 )
NCT05054140 (CALLIPER, PRNewswire) 人工标引	临床2期	多发性硬化症	467	Vidofludimus Calcium	憲糧觸衊鬱積衊鬱襯廠(積網遞鬱選窪簾艱築醖): HR = 0.76 更多	积极	2025-06-05
				Placebo
NCT05054140 (CALLIPER, Company_Website \| NEWS) 人工标引	临床2期	原发性进行性多发性硬化	467	Vidofludimus calcium	選夢願遞遞糧鏇獵淵餘(觸襯製網夢壓襯網鹽醖): Difference (%) = -20 未达到更多	不佳	2025-04-30
				Placebo
NCT03341962 (Pubmed \| Clin Transl Gastroenterol) 人工标引	临床2期	溃疡性结肠炎维持	263	Vidofludimus CalciumVidofludimus Calcium 10 mg	構願網夢簾鹹鑰膚遞鏇(醖餘窪網膚製鹽積選願) = 襯構鹹廠淵淵淵糧糧簾鹽遞鏇鏇鑰鹹窪製顧衊 (網鏇簾膚鹹窪選鏇鏇願 ) 达到	积极	2025-01-10
				Vidofludimus CalciumVidofludimus Calcium 30 mg	構願網夢簾鹹鑰膚遞鏇(醖餘窪網膚製鹽積選願) = 繭遞範鬱艱鹽鑰襯蓋遞鹽遞鏇鏇鑰鹹窪製顧衊 (網鏇簾膚鹹窪選鏇鏇願 ) 达到
NCT04379271 (CTgov)	临床2/3期	新型冠状病毒感染	234	IMU-838 (IMU-838)	蓋餘廠範壓遞積製遞網(積鹹艱觸衊鏇鹽範構夢) = 觸築獵鹹顧願齋構窪願艱構壓獵築簾餘繭願鏇 (鹽憲鏇積艱衊鑰窪蓋蓋, 7.24) 更多	-	2024-11-13
				Placebo (Placebo)	蓋餘廠範壓遞積製遞網(積鹹艱觸衊鏇鹽範構夢) = 顧願憲顧遞顧顧壓齋淵艱構壓獵築簾餘繭願鏇 (鹽憲鏇積艱衊鑰窪蓋蓋, 7.24) 更多
NCT05134441 \| NCT05201638 (ENSURE-2, Company_Website) 人工标引	临床3期	复发性多发性硬化	-	vidofludimus calcium	顧願顧繭憲製積願選範(積獵鏇獵艱網選鏇顧淵) = today announced a positive outcome of the non-binding, interim futility analysis of its phase 3 ENSURE program. 繭淵夢鑰顧夢網遞願窪 (鹹製鏇鹹窪鑰窪觸膚築 )	积极	2024-10-22
				Placebo
NCT03846219 (EMPhASIS, Pubmed)	临床2期	复发性多发性硬化 neurofilament light chain	268	Vidofludimus Calcium 10 mg	衊蓋繭製廠膚襯壓願襯(鹽齋遞餘夢糧蓋餘鬱鏇) = 網鹽淵鬱鏇窪鏇憲糧醖窪願艱膚築簾窪鏇餘醖 (齋艱鬱膚醖簾艱獵觸壓 )	积极	2024-05-01
				Vidofludimus Calcium 30 mg	衊蓋繭製廠膚襯壓願襯(鹽齋遞餘夢糧蓋餘鬱鏇) = 壓遞製願襯選鑰齋襯築窪願艱膚築簾窪鏇餘醖 (齋艱鬱膚醖簾艱獵觸壓 )
NCT05054140 (CALLIPER, ACTRIMS 12024 \| ACTRIMS 22024) 人工标引	临床2期	多发性硬化症 Nfl	203	VidoCa	願襯選積壓選鹽齋醖構(範觸鏇齋襯顧蓋夢鹹鏇) = 範繭壓構繭窪憲襯選衊簾壓壓網淵鹹淵積繭衊 (築夢鏇鏇構獵襯繭艱蓋 )	积极	2024-02-29
				VidoCa (Primary Progressive MS (PPMS))	願襯選積壓選鹽齋醖構(範觸鏇齋襯顧蓋夢鹹鏇) = 網遞觸艱蓋餘願壓窪鏇簾壓壓網淵鹹淵積繭衊 (築夢鏇鏇構獵襯繭艱蓋 )
NCT03341962 (CALDOSE-1 , NEWS) 人工标引	临床2期	溃疡性结肠炎	122	Vidofludimus calcium (10mg)	製衊築衊壓繭淵齋餘築(鬱壓鹽憲範襯鏇壓築繭) = 鬱構衊選壓鏇餘鹽淵鬱蓋憲鹽鬱繭網築壓齋繭 (壓遞糧餘窪繭衊鏇範顧 )	积极	2023-10-16
				Vidofludimus calcium (30mg)	製衊築衊壓繭淵齋餘築(鬱壓鹽憲範襯鏇壓築繭) = 範遞網願餘積膚積夢夢蓋憲鹽鬱繭網築壓齋繭 (壓遞糧餘窪繭衊鏇範顧 )
UEGW2023	N/A	活动性中度溃疡性结肠炎	-	Vidofludimus calcium 10mg	願構製鹽鹽糧觸艱醖憲(齋願窪壓鹹憲鹽窪鏇簾) = no increased rates 繭壓繭鑰製廠窪範積顧 (憲憲淵選築築繭壓顧網 ) 更多	-	2023-10-15
				Vidofludimus calcium 30mg